Wahlstrom Mats

Director Wahlstrom buys 60,000 TLSI shares at $2.53; holdings up 68.5% to 147.6K, stock -61.9% from 52-week high, but 3 prior same-ticker buys showed 100% well-timed at 90-day horizon.

Wahlstrom Mats, a director of TriSalus Life Sciences, purchased 60,000 shares at $2.53 on 2026-05-15 (total value $151,800.00), expanding his holdings by 68.5% to 147.6K shares. This purchase arrives after a sharp equity price decline: the stock is -61.9% from its 52-week high of $7.95 and down -34.8% in the past 30 days. The timing signal, however, appears instructive: across his 3 prior open-market transactions at TLSI (November 2024), Wahlstrom's buys exhibited a 100% well-timed rate at the 90-day horizon, with subsequent returns ranging from +25.7% to +36.8%, despite negative 30-day returns (-2.6% to -11.0%) on those same trades. This pattern suggests Wahlstrom has historically purchased when TLSI shares were depressed in the near term yet recovered materially within 90 days. Underlying fundamentals show the company posted $8.9M revenue and $1.5M net income last quarter, with +53.4% annual revenue growth, though it remains unprofitable on a full-year basis. Investors should monitor whether this 60,000-share accumulation follows the same rebound trajectory Wahlstrom's prior three purchases at this ticker have exhibited.

Director Mats Wahlstrom bought 5,000 shares at $4.55; now holds 15,727 shares (+46.6%)

Wahlstrom purchased 5,000 shares at $4.55 on 2024-11-22, increasing his holdings to 15,727 shares (+46.6% relative to pre-transaction holdings). The stock is down -60.3% from its 52-week high of $10.25 and currently trades at $4.07, just 12.5% below the acquisition price. The company is unprofitable (full-year net income was negative) but shows strong revenue growth of +49.3% year-over-year, with latest quarterly revenue at $7.3M. This purchase occurred immediately after two other buys by the same director on 2024-11-20 and 2024-11-21, representing concentrated accumulation over three consecutive trading days. The director's 2 prior cross-ticker open-market buys show no track record of achieving positive 90-day returns, and his TLSI outcomes are not yet measurable.

Director Wahlstrom Mats buys 10.7K shares of TLSI across 2 transactions (Nov 20–21) for $47.1K at blended avg $4.39

Director Wahlstrom Mats purchased 10,727 shares across 2 separate transactions at TriSalus Life Sciences on November 20–21, 2024, at a blended average price of $4.39, representing his first open-market purchase at this ticker. The company is unprofitable (net income of $-2,399,000.00 in the latest quarter) but showing strong annual revenue growth of +49.3%, with current market cap of $138,133,910.61. The stock is currently trading at $4.53, down -55.8% from its 52-week high of $10.25 but up +12.4% over the past 30 days. This marks an established insider establishing a meaningful new position in a micro-cap biotech with volatile price action and fundamental losses, warranting monitoring of company operational milestones and burn rate.